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Abstract
Background: The purpose of this study was to determine whether sedentary obese women with knee OA
initiating an exercise and weight loss program may experience more beneficial changes in body composition,
functional capacity, and/or markers of health following a higher protein diet compared to a higher carbohydrate
diet with or without GCM supplementation.
Methods: Thirty sedentary women (54 ± 9 yrs, 163 ± 6 cm, 88.6 ± 13 kg, 46.1 ± 3% fat, 33.3 ± 5 kg/m
2) with
clinically diagnosed knee OA participated in a 14-week exercise and weight loss program. Participants followed an
isoenergenic low fat higher carbohydrate (HC) or higher protein (HP) diet while participating in a supervised 30-
minute circuit resistance-training program three times per week for 14-weeks. In a randomized and double blind
manner, participants ingested supplements containing 1,500 mg/d of glucosamine (as d-glucosamine HCL), 1,200
mg/d of chondroitin sulfate (from chondroitin sulfate sodium), and 900 mg/d of methylsulfonylmethane or a
placebo. At 0, 10, and 14-weeks, participants completed a battery of assessments. Data were analyzed by MANOVA
with repeated measures.
Results: Participants in both groups experienced significant reductions in body mass (-2.4 ± 3%), fat mass (-6.0 ± 6%),
and body fat (-3.5 ± 4%) with no significant changes in fat free mass or resting energy expenditure. Perception of
knee pain (-49 ± 39%) and knee stiffness (-42 ± 37%) was decreased while maximal strength (12%), muscular
endurance (20%), balance indices (7% to 20%), lipid levels (-8% to -12%), homeostasis model assessment for
estimating insulin resistance (-17%), leptin (-30%), and measures of physical functioning (59%), vitality (120%), and
social function (66%) were improved in both groups with no differences among groups. Functional aerobic capacity
was increased to a greater degree for those in the HP and GCM groups while there were some trends suggesting
that supplementation affected perceptions of knee pain (p < 0.08).
Conclusions: Circuit style resistance-training and weight loss improved functional capacity in women with knee
OA. The type of diet and dietary supplementation of GCM provided marginal additive benefits.
Trial Registration: ClinicalTrials.gov: NCT01271218
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According to the Centers for Disease Control and Preven-
tion (CDC), there are approximately 43 million Americans
suffering from arthritis with 21 million affected by osteoar-
thritis (OA) [1,2]. It is believed that 1 in 10 or 4.3 million
adults aged 60 and older in the United States of America
have symptomatic knee OA [3] and 1 in 4 individuals may
develop knee and/or hip OA during their lifetime [2]. The
general incidence and prevalence of OA increases two to
tenfold from age 30 to 65 years [4]. By 2020, the CDC esti-
mates that 60 million Americans will have OA [1,2]. For-
mer athletes and active individuals have been reported to
b es u s c e p t i b l et ok n e eO Aa st h e ya g e[ 5 ] .
Symptoms of OA include disability of the joints caused
by swelling, pain after exercise or use, and joint stiffness
[1,2]. Although the cause of OA is unknown, it is believed
that stress placed upon the join t si saf a c t o r .T r e a t m e n t s
for OA vary and have included rest, heat, anti-inflamma-
tory and pain-relieving medications, corticosteroid injec-
tions, and/or surgery [5]. Physical activity has been
suggested to be beneficial for OA patients while inactivity
can serve as a risk factor for developing OA [5]. Research
from the Framingham Knee Osteoarthritis Study indi-
cated that overweight men and women have a higher risk
for developing OA than those who are not overweight [6].
These researchers also reported that weight loss helped
decrease pain associated with OA [7]. Messier and collea-
gues [8] reported that weight loss significantly reduces
load exertion on the knee. Moreover, Miller and associ-
ates [9] reported that an intensive energy deficit diet com-
bined with exercise training improved physical function
indices in older obese adults with knee OA. It has been
reported that changes in OA symptoms were best pre-
dicted by changes body fat [10]. In addition, reductions in
strength relative to body weight can promote the develop-
ment of OA [11]. As a result, interventions that
strengthen the muscles and reduce body fat have been
suggested to reduce pain and enhance functional capacity
in individuals with OA [10,12,13].
Higher protein diets have been reported to promote
greater weight loss while preserving fat free mass and rest-
ing energy expenditure to a greater degree than higher
carbohydrate diets [14-16]. In addition, higher protein
diets have been reported to promote greater improvement
in several markers of health particularly in populations at
risk to cardiovascular disease due to elevated glucose and/
or triglyceride levels [17-19]. Prior research from our lab
has indicated that 14-weeks of circuit style resistance-
training while following a moderately hypo-energetic
higher protein diet promoted significant reductions in
weight and fat mass while improving fitness and markers
of health in obese women [20,21]. A subsequent study
indicated that this program was comparatively more
effective in terms of promoting weight loss and improve-
ments in markers of health and fitness than a meal repla-
cement-based diet program with recommendations to
increase physical activity [22]. Additionally, we have
reported that higher protein diets promote more favorable
changes in body composition and markers of health than a
higher carbohydrate diet in obese women initiating train-
ing with and without insulin resistance [23]. Theoretically,
adherence to a higher protein weight loss diet while parti-
cipating in a resistance-training program may be more
beneficial than a higher carbohydrate diet for patients with
OA because it may promote greater reductions in fat
mass, preserve fat free mass during weight loss, and
promote greater improvements in functional status and
markers of health.
Glucosamine sulfate supplementation in patients with
knee pain has been reported to improve joint pain and
function [24]. For example, Pavelka and colleagues [25]
evaluated the effects of 3-years of glucosamine sulfate
supplementation on progressive joint degeneration and
symptoms associated with knee OA. Results indicated that
markers of knee pain, physical function, and joints stiffness
were improved. Similarly, Usha and coworkers [26]
studied the efficacy and safety of combinations of glucosa-
mine and methlysulfonylmethane (MSM) supplementation
in patients with knee OA. The researchers found that sup-
plementation with glucosamine and MSM reduced joint
pain and swelling, while improving the physical function
of the joints [26]. These findings and others indicate that
glucosamine, chondroitin, and/or MSM supplementation
may have some therapeutic benefits for OA patients. For
this reason, dietary supplementation of glucosamine,
chondroitin, and/or MSM has been recommended parti-
cularly for active individuals [5,27-29]. Theoretically,
glucosamine, chondroitin, and MSM supplementation
may provide additive benefits to individuals with knee OA
initiating an exercise and weight loss program.
The purpose of this study was 1) to determine whether
sedentary obese women with knee OA initiating an exer-
cise and weight loss program will experience more favor-
able changes in body composition, functional status, and/
or markers of health when following a higher protein diet
compared to a higher carbohydrate-based diet; 2) to
determine whether dietary supplementation of glucosa-
mine, chondroitin, and MSM during a weight loss and
exercise program lessens symptoms of pain, improves
functional capacity, and/or promotes greater health bene-
fits in women with knee OA; and, 3) to determine
whether there are any additive benefits of combining
these strategies. It was hypothesized that all participants
would experience beneficial changes in body mass, body
composition, functional status, and markers of health.
However, greater benefits would be observed in those
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droitin, and MSM supplementation.
Methods
Experimental design
The study was conducted as a randomized, double-
blind, placebo-controlled parallel clinical trial conducted
in a university research setting. Participants with physi-
cian diagnosed OA participated in the Curves
® (Curves
International, Waco, TX) fitness and weight manage-
ment program for 14-weeks [30]. This program was
selected because it offers higher carbohydrate and higher
protein diets; incorporates circuit-style resistance train-
ing as the primary exercise modality; it has been found
to be effective in promoting weight loss and improving
markers of health and fitness in sedentary obese women
[20-23]; it offers a joint support supplement containing
GCM to its members; and, the program is widely avail-
able. Participants were randomly assigned to ingest in a
double-blind and randomized manner either a placebo
or a commercially available dietary supplement contain-
ing glucosamine, chondroitin, and MSM. Primary out-
come measures included measures of pain and
functional capacity. Secondary outcome measures
included weight loss and body composition; serum
blood and hormones; and, measures of quality of life.
All participants were tested for changes in energy intake;
anthropometrics; body composition; resting energy
expenditure; cardiovascular and muscular fitness; bal-
ance and functional capacity; serum and whole blood
clinical markers; hormonal profiles; pain indices; and,
psychosocial parameters after 0, 10, and 14 weeks of
training, dieting, and supplementation.
Participants
This research protocol was reviewed and approved by the
university Institutional Review Board prior to initiation.
Participants were recruited through area physicians,
advertisements in local newspapers, campus flyers, and
Internet advertisements. Interested participants were
asked to contact the laboratory for an initial telephone
pre-screening interview. General entrance criteria
included being a female with physician diagnosed OA
between the ages of 18-70 years with a body mass index
(BMI) greater than 27 kg/m
2 and no recent participation
in a diet or exercise program. Individuals who met initial
entrance criteria were invited to attend a familiarization
session in which the details of the study were explained,
human subject consent forms were signed, and personal
and medical history information obtained. Subjects were
not allowed to participate in this study if they: 1.) were
pregnant, became pregnant, or had a desire for preg-
nancy; 2.) had any metabolic disorder including known
electrolyte abnormalities, heart disease, arrhythmias, dia-
betes, or thyroid disease; 3.) had a history of hyperten-
sion, hepatorenal, musculoskeletal, autoimmune, or
neurological disease (other than knee OA); 4.) were tak-
ing thyroid, hyperlipidemic, hypoglycemic, or anti-hyper-
tensive medications; 5.) had taken ergogenic levels of
nutritional supplements that may affect muscle mass
(e.g., creatine, HMB), anabolic/catabolic hormone levels
(e.g., DHEA), or weight loss supplements (e.g., thermo-
genics) within three months prior to the start of the
study; 6.) were ingesting any anti-inflammatory products
two weeks before the start of the study or additional pro-
ducts during the study; 7.) reported any unusual adverse
events associated with this study in which the supervising
physician recommended removal from the study; 8.) had
significant injury or surgery to the lower extremity or
spine within the last six months; 9.) did not indicate a
minimal amount of perceived pain and physical function
limitation on inventories used in the study; 10.) had
severe arthritis that required surgery and greatly limited
functionality (inability to perform lunge); or, 11.) had
arthritis that required the current use of physiotherapy
modalities.
Figure 1 presents a flow diagram of study enrollment,
allocation, follow-up, and analysis. A total of 42 women
met initial phone screening criteria and were invited to
familiarization sessions. Of these, 32 women met
entrance criteria and were medially-cleared to participate
in the study by a research nurse and their personal physi-
cian. A total of 30 women completed the study. Those
who dropped out of the study did so due to time con-
straints unrelated to the exercise, diet, and/or supple-
mentation program. Participants were 54 ± 9 years old,
163 ± 6 cm tall, weight 88.6 ± 13 kg, had a body fat per-
centage of 46.1 ± 3%, and had a BMI of 33.3 ± 5 kg/m
2.
Figure 1 Participant flow diagram.
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Participants underwent a detailed orientation and famil-
iarization/practice session prior to baseline testing. This
included an explanation of the methods of the study
and how to adhere to the diet; an opportunity to prac-
tice testing procedures; and, familiarization to the exer-
cise training equipment. Participants recorded all food
and fluid intake on dietary record forms 4-days before
each testing session for weeks 0, 10, 14. The dietary
record included three days during the week and one
weekend day. Participants were also asked to refrain
from vigorous physical activity, alcohol intake, and
ingestion of over the counter medications for 24-hours
prior to testing. In addition, participants fasted for
12-hours prior to reporting to the laboratory. All testing
was conducted in the early morning hours in order to
control for diurnal variations in hormone levels.
Once reporting to the lab, participants completed a
series of questionnaires that included the SF-36 quality
of life (QOL) inventory; a Visual Analog Scale (VAS) to
assess knee pain; and, the Western Ontario and McMas-
ters University Osteoarthritis Index to assess knee func-
tion. Participants were then weighed, had total body
water determined by multi-frequency bioelectrical impe-
dance (BIA), and had body composition determined
using dual-energy x-ray absorptiometry (DEXA). Follow-
ing these assessments, participants had their blood pres-
sure and resting heart rate determined using standard
procedures. Participants then donated approximately
20 ml of fasting blood using venipuncture techniques of
an antecubital vein in the forearm according to standard
procedures. Following blood collection, participants had
measurements taken of their knees to include knee cir-
cumference to determine swelling secondary to osteoar-
thritis and active range of motion to assess knee flexibility.
The participants then performed sit to stand, step-up and
over, and forward lunge balance and functional capacity
assessments. Participants then performed a knee extension
and flexion muscular strength and endurance test using an
isokinetic dynamometer. Next, participants performed a
maximal cardiopulmonary exercise stress test to assess
symptom limited functional peak aerobic capacity. Finally,
participants performed an upper body muscular strength
and endurance bench press test. Participants completed
weekly a medical safety/side effect report that was ana-
lyzed by the lab research nurse.
Dietary intervention
All subjects followed the Curves
® exercise and weight
loss program (Curves International, Waco, TX)t h a ti s
designed to improve fitness and promote weight loss in
women [30]. Participants were assigned to follow isoener-
getic low fat diets with higher protein (HP) or higher
carbohydrate (HC) macronutrient content based on their
responses to a carbohydrate tolerance questionnaire as
per diet guidelines. In both diets, participants were
instructed to consume 1,200 kcals/d for 1-week (Phase I)
and 1,600 kcals/d for 9-weeks (Phase II) during a
10-week active weight loss period. Participants following
the HC diet were instructed to consume a diet containing
55% carbohydrate, 15% protein, and 30% fat. Subjects in
the HP group were asked to follow a diet containing 7%
carbohydrate, 63% protein, and 30% fat during Phase I of
the diet and 15% carbohydrate, 55% protein, and 30% fat
during Phase II of the diet. The final 4-weeks of the diet
(Phase III) served as a weight maintenance period. Parti-
cipants were instructed to consume 2,600 kcals d
-1 con-
sisting of 55% carbohydrate, 15% protein, and 30% fat
and to follow their respective Phase I diet (1,200 kcals/d)
for 2-days only if they gained 1.35 kg (3 lbs) during the
maintenance period. Participants were given diet plans
and menus to follow at the start of the study and met
with a registered dietitian and/or exercise physiologist at
each testing session and every two weeks during the
course of the study to discuss diet and exercise compli-
ance. Previous research has demonstrated that this
14-week program promoted a 3-5 kg weight loss while
maintaining resting energy expenditure in sedentary
obese women [20-23].
Supplementation protocol
Participants were randomly assigned to ingest in a double-
blind manner caplets containing a commercially available
supplement containing GCM (Curves Joint and Connective
Support™, Curves International, Waco, TX) or a similarly
prepared dextrose containing placebo (P) for double blind
administration. The GCM supplement provided a total of
1,500 mg/d of glucosamine (from d-glucosamine HCL),
1,200 mg/d of chondroitin sulfate (from chondroitin sulfate
sodium), 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/
do fz i n c ,9 0 0m g / do fM S M ,3 0 0m g / do fb o s w e l l i as e r -
rata extract, 180 mg/d of white willow bark extract, and
15 mg/d of rutin powder. Participants ingested three
caplets in the morning and the remaining three caplets in
the evening 30-min before a meal for 14-weeks. The sup-
plements were prepared in caplet form and packaged in
generic bottles for double blind administration by Nutra
Manufacturing (Greenville, SC). The dextrose placebo was
prepared with a similar base material and color coated in
order to have a similar appearance and aroma as the GCM
supplement. Supplementation compliance was monitored
by having the participants return empty bottles of the sup-
plement at the end of each testing phase. In addition,
internal monitoring of supplementation compliance
occurred with participants signing a compliance statement
in a post-study questionnaire.
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All subjects participated in the Curves supervised exercise
program three days per week throughout the fourteen
week protocol (a total of 42 workouts). Each circuit-style
workout consisted of 14 exercises (e.g. elbow flexion/
extension, knee flexion/extension, shoulder press/lat pull,
hip abductor/adductor, chest press/seated row, horizontal
leg press, squat, abdominal crunch/back extension, pec
deck, oblique, shoulder shrug/dip, hip extension, side
bends and stepping). The exercise machines contained
calibrated pneumatic resistance pistons that allowed for
opposing muscle groups to be trained in a concentric-only
fashion. Participants were informed of proper use of all
equipment and were instructed to complete as many repe-
titions in a 30-s time period. In a continuous, interval fash-
ion, participants performed floor-based callisthenic (e.g.
running/skipping in place, arm circles, etc.) exercises on
recovery pads for a 30-s time period after each resistance
exercise in an effort to maintain a consistent exercise
heart rate that corresponded to 60% to 80% of their heart
maximum heart rate. All workouts were supervised by
trained fitness instructors who assisted with proper exer-
cise technique and maintenance of adequate exercise
intensity. Participants were required to complete two rota-
tions through all exercises which corresponded to exercis-
ing for approximately 28-min followed by a standardized
whole-body stretching routine. Compliance to the exercise
program was set a priori at a minimum of 70% compliance
(30/42 exercise sessions).
Procedures
Diet assessment
Participants recorded all food and fluid intake for four
days prior to each testing session. This included three
weekdays and one weekend day. Dietary inventories were
reviewed by a registered dietitian and subsequently ana-
lyzed for average energy and macronutrient intake using
the ESHA Food Processor (Version 8.6) Nutritional Analy-
sis software (ESHA Research Inc., Salem, OR).
Body composition
Height and body mass were determined according to stan-
dard procedures using a calibrated electronic scale (Cardi-
nal Detecto Scale Model 8430, Webb City, Missouri)w i t ha
precision of +/-0.02 kg. Intracellular, extracellular, and
total body water was assessed using a Xitron 4200 Bioelec-
trical Impedance Analyzer (Xitron Technologies, Inc., San
Diego, CA) in order to monitor hydration status among
testing sessions. Bone density and body composition
(excluding cranium) were assessed using a Hologic Discov-
ery W (Hologic Inc., Waltham, MA)d u a le n e r g yx - r a y
absorptiometer (DXA) equipped with APEX Software
(APEX Corporation Software, Pittsburg, PA). Mean
coefficients of variation for bone mineral content and bone
mineral density measurements performed on the spine
phantom ranged between 0.41 - 0.55%. Test-retest reliabil-
ity studies performed with this DXA machine have pre-
viously yielded mean coefficients of variation for total bone
mineral content and total fat free/soft tissue mass of 0.31 -
0.45% with a mean intra-class correlation of 0.985 [31].
Resting energy expenditure
Resting energy expenditure (REE) was assessed using a
ParvoMedics TrueMax 2400 Metabolic Measurement Sys-
tem (ParvoMedics, Inc., Sandy, UT). This test was a non-
exertional test performed in a fasted state with the partici-
pants lying supine on an exam table. A clear, hard plastic
hood and soft, clear plastic drape was placed over the
participants’ neck and head in order to determine resting
oxygen uptake and energy expenditure. All participants
remained motionless without falling asleep for approxi-
mately 20 minutes. Data were recorded after the first ten
minutes of testing during a five minute period of time in
which criterion variables (e.g., VO2 L/min) changed less
than 5%. Test-retest measurements on 14 participants
from a study previously reported [20] revealed that test-
retest correlations (r) of collected VO2 in l/min ranged
from 0.315 - 0.901 (X : 0.638) and coefficient of variation
ranged from 8.2% - 12.0% (X :9 . 9 %) with a mean intra-
class coefficient of 0.942, p < 0.001.
Anthropometrics
Active range of motion for right/left knee extension and
flexion was measured with a standard 12” goniometer to
determine knee range of motion. The participant was
made to lie supine with one leg extended and the other leg
bent with the heel resting on table. The extended leg was
measured for knee extension. Next, the measurement of
the same leg was measured for flexion range of motion by
having the participant raise the extended leg slightly off
the table and bring the heel toward the gluteus maximus.
These procedures were repeated on the opposite leg. Test
to test reliability of performing these tests were 0.75-0.98.
Knee circumference was measured as a general indicator
of knee inflammation/swelling. The participant lied supine
with one leg extended and the other leg bent with the heel
resting on table. The circumference of the extended leg
was measured and then repeated on the opposite leg. Mea-
surements were performed utilizing a Gulick anthropo-
metric tape (Model J00305, Lafayette Instruments,
Lafayette, IN) at the joint line of both knees. Test to test
reliability of performing these tests were 0.86-0.92.
Exercise capacity
Resting heart rate was determined by palpitation of the
radial artery using standard procedures [32]. Blood
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artery using a mercurial sphygmomanometer using stan-
dard clinical procedures [32]. Resting heart rate and
blood pressure measurements were taken on the partici-
pant in the supine position after resting for 5-min. Parti-
cipants were attached to the Quinton 710 ECG (Quinton
Instruments, Bothell, WA) and walked on a Trackmaster
TMX425C treadmill (JAS Fitness Systems, Newton, KS).
Resting expired gases were collected using the Parvo
Medics 2400 TrueMax Metabolic Measurement System.
The participant then performed a standard symptom-
limited maximal Bruce treadmill exercise test according
to standard procedures [32]. Calibration of gas and flow
sensors was completed every morning prior to testing
and was found to be within 3% of the previous calibra-
tion point.
A standard isotonic Olympic bench press (Nebula Fit-
ness, Versailles, OH) was used for the isotonic bench press
tests. A one repetition maximum (1 RM) test was per-
formed using standard procedures. Following determina-
tion of the participants 1RM, subjects performed a bench
press muscular endurance test at 70% of 1RM. Test to test
reliability of performing these strength tests in our lab on
resistance-trained participants have yielded low mean coef-
ficients of variation and high reliability for the bench press
(1.9%, intra-class r = 0.94).
Isokinetic testing was performed using the Biodex Mul-
tijoint Isokinetic Testing System (Biodex Medical Systems,
Shirley, NY) to measure knee strength and endurance. Iso-
kinetic strength was assessed bilaterally. Testing began
from a dead stop with the participants’ leg at 90 degrees of
flexion and consisted of five, ten, and fifteen maximal
voluntary concentric reciprocal knee extension and flexion
repetitions at three different test speeds. Velocities were
presented in a fixed order at 60, 180 and 300 degrees per
second with one-minute rest between bouts. Fatigue index
was calculated as the change in average force produced
from the first to last third of each set of work performed.
Positive values represent the percentage decline in force
generation over the set while negative values represent an
increase in average force generated at the latter third of
the set of repetitions. Test-to-test reliability data for
women with osteoarthritis has been reported to vary from
0.83 to 0.94 [33].
Balance and functional assessment
Measurements of balance and functional capacity were
obtained using the Neurocom SmartEquitest
® (Neuro-
com International, Portland, OR). Data were collected
on postural balance and mobility utilizing the sit to
stand, step up and over, and forward lunge tests follow-
ing standardized procedures. Test-to-test reliability in
women aged 65-75 has been reported to be r = 0.92
[34].
Blood collection and analysis
Fasted whole blood and serum samples were collected
using standard phlebotomy techniques. Whole blood
samples were analyzed for complete blood counts with
platelet differentials using an Abbott Cell Dyn 3500
(Abbott Laboratories, Abbott Park, IL) automated hema-
tology analyzer. Serum samples were analyzed for a
complete metabolic panel using a calibrated Dade Behr-
ing Dimension RXL (Siemans AG, Munich, Germany)
automated clinical chemistry analyzer. Coefficient of
variation (CV) for the tests using this analyzer was simi-
lar to previously published data for these tests (range:
1.0 to 9.6%) [35].
Serum C-Reactive Protein, IL-6, TNF-a,c o r t i s o l ,a n d
leptin were determined with either enzyme linked
immuno-absorbent assay (ELISA) or enzyme immuno-
absorbent assay (EIA) kits (Cayman Chemical, AnnArbor,
MI; Diagnostic Systems Laboratories, Webster, TX) using a
Wallac Victor-1420 microplate reader (Perkin-Elmer Life
Sciences, Boston, MA) at a dual wavelength absorbance of
405 or 450 nm according to kit specifications. Intra-assay
and inter-assay coefficient of variation were, respectively,
5.3-6.7% and 8.2-9.7% for TNF-a; 4.7-8.3% and 6.70-10.0%
for IL-6; 6.9% and 13.1% for C-Reactive protein; and,
2.4-10.3%, and 8.0-12.0% for cortisol. The homeostasis
model assessment for estimating insulin resistance
(HOMAIR) was calculated as the product of fasting glu-
cose times fasting insulin expressed in conventional units
divided by 405 [36].
Psychosocial and pain questionnaires
Participants completed the SF-36 Quality of Life (QOL)
inventory to determine changes in quality of life scores
throughout the length of the study [37]. The SF-36 QOL
inventory assesses a number of physical and mental com-
ponents including physical functioning (i.e., ability to
perform most vigorous physical activities without limita-
tion to health); role physical (i.e., ability to work and per-
form daily activities); bodily pain (i.e., limitations due to
pain); general health (i.e., assessment of personal health);
vitality (i.e., feelings of energy); social functioning (i.e.,
ability to perform normal social activities); role emotion
(i.e., problems with work or other daily activities); and,
mental health (state of feelings of peacefulness, happi-
ness, and calm). This instrument has been shown to be a
valid indicator of psychosocial dimensions that may be
influenced by general improvements in health and/or
weight loss. Perceived knee pain was determined using a
Visual Analogue Scale (VAS) following procedures devel-
oped by Denegar & Perrin [38]. In addition, the Western
Ontario and McMasters University Osteoarthritis Index
(WOMAC™ 3.1 Index) was used to assess dimensions of
pain, joint stiffness and disability in knee and hip osteoar-
thritis using a battery of 24 questions [39].
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Baseline demographic data (i.e., age, height, weight, per-
cent body fat, BMI) were analyzed by one-way analysis
of variance (ANOVA). Data were normally distributed
and did not require transformation prior to statistical
analysis. Related variables were grouped together and
analyzed by multivariate analysis of variance (MAN-
OVA) with repeated measures (PASW Statistics 18.0.2
[Release April 2, 2010], SPSS Headquarters, Chicago, IL).
Non-correlated variables were analyzed by repeated
measures ANOVA. Delta values were calculated and
analyzed on select variables by ANOVA for repeated
measures to assess changes from baseline values. Data
were considered statistically significant when the prob-
ability of type I error was 0.05 or less. In some
instances, quadratic interaction p-levels are reported
indicating that non-linear but significant differences
were observed between groups over time. Tukey’sL e a s t
Significant Difference (LSD) post-hoc analyses were per-
formed when a significant interaction was observed to
determine where significance was obtained. Effect sizes
were calculated using Cohen’s d statistic to quantify the
size and significance that may exist between groups
independent of group size. Power calculations on
changes observed in WOMAC scores indicated that an
n-size of 8-10 per group would yield sufficient power
(> 0.8) values. Additionally, power calculations on
weight loss changes previously observed in similar stu-
dies indicated that a sample size of 10-15 per group
yielded moderate to high power (> 0.8) values [20-22].
Results
A total of 30 participants completed the study (54 ± 9 yrs,
163 ± 6 cm, 88.6 ± 13 kg, 46.1 ± 3% fat, 33.3 ± 5 kg/m
2).
Of these, 16 participants in the GCM group completed
the study (52 ± 10 yrs, 164 ± 7 cm, 89.7 ± 13 kg, 45.9 ±
3% fat, 33.3 ± 4 kg/m
2) while 14 participants in the P
group completed the study (57 ± 7 yrs, 162 ± 6 cm, 87.3 ±
14 kg, 46.4 ± 4% fat, 33.2 ± 5 kg/m
2). No significant differ-
ences were observed between groups on baseline demo-
graphic data.
Energy intake
Table 1 presents dietary intake data observed for the
diet and supplement groups. The diet intervention sig-
nificantly reduced energy intake in both groups over
time. As expected, carbohydrate intake was greater in
the HC group while protein intake was greater in the
HP group during the 10-week diet phase. Dietary sup-
plementation had no influence on macronutrient intake.
Body composition and resting energy expenditure
Table 2 presents body composition and REE results
observed among groups during the course of the study
while Figure 2 presents changes from baseline in body
composition values. Dieting and training significantly
decreased body mass (-2.1 ± 3 kg or -2.4 ± 3%), fat
mass (-2.3 ± 2.4 kg or -6.0 ± 6%), and percent body fat
(-1.6 ± 1.9% or -3.5 ± 4%) in both groups over time
while fat free mass and REE were maintained. Type of
diet and supplementation had no significant effects on
changes in body composition or REE.
Knee anthropometric measurements
Table 3 presents knee range of motion and circumfer-
ence data. No significant time × diet, time × supplement,
or time × diet × supplement interactions were observed
among groups in knee range of motion or circumference
measures. However, left leg knee extension and flexion
r a n g eo fm o t i o nw a ss i g n i f i c a n t l yi m p r o v e do v e rt i m ei n
both groups as a result of training.
Exercise capacity
Table 4 shows peak aerobic capacity, upper body muscular
strength, and upper body muscular endurance data
observed throughout the study. Exercise training signifi-
cantly increased symptom-limited peak VO2 (5%), bench
press 1RM strength (12%), and upper body bench press
muscular endurance at 70% of 1RM (20%). Peak aerobic
capacity was increased to a greater degree in the HP and
GCM groups. No significant time × diet, time × supple-
ment, or time × diet × supplement interactions were
observed among groups in bench press 1RM strength or
endurance. However, participants in the HP group pro-
duced more total lifting volume during the muscular
endurance test than those in the HC group. Exercise train-
ing, diet, and supplementation had no effects on resting
heart rate, systolic blood pressure or diastolic blood
pressure.
Results from isokinetic knee extension and flexion tests
are presented in Table 5. No significant group or group ×
time interactions were observed. Therefore, data are pre-
sented for mean time effects. Training significantly
increased knee extension and flexion peak torque values in
each set of maximal voluntary contractions studied. Aver-
age gains in knee extension peak torque strength was
8-13% when performing 5 repetitions at 60 deg/sec,
12-22% when performing 10 repetitions at 180 deg/sec,
and 12-19% when performing 15 repetitions at 300 deg/
sec. Similarly, knee flexion peak torque increased by
26-28%, 45-46%, and 30-38% during the three exercise
bouts, respectively. There was also evidence that training
influenced fatigue index responses.
Balance and functional capacity
Table 6 presents functional balance testing results. No
significant group or group × time interactions were
observed. Therefore, data are presented for mean time
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index, or sway velocity measures obtained during the sit
to stand test. However, lift-up index increased by 8-12%
and movement time decreased by 15% in the step up
and over knee function test. In the forward lunge knee
function test, lunge distance was significantly increased
(7-9%) while contact time (-19 to -20%) and force
impulse (-17 to -19%) values decreased.
Blood samples
Table 7 shows serum blood and hormone markers
observed among groups during the study. No significant
group or group × time interactions were observed
among groups. Therefore, data are presented for mean
time effects. Training and dieting significantly decreased
total cholesterol (-8%), low-density lipoproteins (-12%),
high density lipoproteins (-12%), blood urea nitrogen
Table 1 Dietary intake data for the diet and supplement groups
Variable Group 0 Week
10
14 p-value
Energy Intake
(kcals/d)
HC-GCM 2,356 ± 690 1,906 ± 571 2,001 ± 241 D = 0.08
HC-P 1,760 ± 695 1,689 ± 439 1,837 ± 617 S = 0.64
HP-GCM 1,775 ± 424 1,398 ± 411 1,441 ± 295 T = 0.06q
HP-P 1,696 ± 361 1,562 ± 165 1,903 ± 274 T × D = 0.80
HC 1,987 ± 730 1,768 ± 475 1,896 ± 503 T × S = 0.18
HP 1,746 ± 377 1,459 ± 333 1,614 ± 358 T × D × S = 0.94
GCM 2,046 ± 610 1,623 ± 527 1,690 ± 390
P 1,741 ± 593 1,651 ± 372 1,857 ± 521
Mean 1,886 ± 605 1,638 ± 439† 1,778 ± 459
Carbohydrate
(g/d)
HC-GCM 342 ± 103 228 ± 87 248 ± 57 D = 0.02
HC-P 189 ± 82 218 ± 70 238 ± 117 S = 0.94
HP-GCM 191 ± 65 125 ± 61 151 ± 38 T = 0.015 q
HP-P 216 ± 39 143 ± 106 269 ± 58 T × D = 0.63
HC 245 ± 115 221 ± 72 241 ± 96 T × S = 0.07
HP 200 ± 55 132 ± 76 196 ± 84 T × D × S = 0.12q
GCM 256 ± 11 171 ± 87† 194 ± 67
P 197 ± 71 196 ± 84 247 ± 100†
Mean 226 ± 94 184 ± 85† 222 ± 88
Protein
(g/d)
HC-GCM 88 ± 24 81 ± 22 75 ± 20 D = 0.22
HC-P 76 ± 24 77 ± 16 79 ± 22 S = 0.97
HP-GCM 79 ± 4 101 ± 31 83 ± 14 T = 0.019q
HP-P 63 ± 11 133 ± 70 76 ± 11 T × D = 0.017q
HC 80 ± 23 77 ± 16 78 ± 20 T × S = 0.35
HP 73 ± 10 113 ± 47† 80 ± 13 T × D × S = 0.19q
GCM 83 ± 16 92 ± 28 80 ± 16
P 72 ± 21 94 ± 44 78 ± 19
Mean 77 ± 19 93 ± 37† 79 ± 17
Fat
(g/d)
HC-GCM 78 ± 24 78 ± 24 82 ± 10 D = 0.25
HC-P 70 ± 39 59 ± 18 62 ± 19 S = 0.26
HP-GCM 79 ± 21 52 ± 21 59 ± 22 T = 0.085q
HP-P 65 ± 32 53 ± 6 63 ± 8 T × D = 0.50
HC 73 ± 33 65 ± 20 69 ± 19 T × S = 0.85
HP 74 ± 24 53 ± 16 60 ± 18 T × D × S = 0.33
GCM 79 ± 21 63 ± 23 69 ± 21
P 63 ± 35 60 ± 15 62 ± 16
Mean 73 ± 29 60 ± 19† 65 ± 18
Data are means ± standard deviations. HC = high carbohydrate diet, HP = high protein diet, GCM = glucosamine/chondroitin/MSM group, P = placebo group, FFM = fat
free mass, REE = resting energy expenditure, D = diet, S = supplement, T = time. q = quadratic alpha level. † Indicates p < 0.05 difference from baseline.
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Variable Group 0 Week
10
14 p-value
Weight
(kg)
HC-GCM 88.0 ± 14 87.0 ± 16 87.4 ± 13 D = 0.75
HC-P 86.8 ± 13 84.8 ± 14 84.1 ± 13 S = 0.70
HP-GCM 91.0 ± 13 89.2 ± 14 87.9 ± 13 T = 0.001
HP-P 88.2 ± 17 86.4 ± 15 86.8 ± 15 T × D = 0.60
HC 87.4 ± 13 85.8 ± 14 85.5 ± 14 T × S = 0.84
HP 90.0 ± 14 87.6 ± 14 87.5 ± 13 T × D × S = 0.10
GCM 89.7 ± 13 87.6 ± 14 87.7 ± 14
P 87.3 ± 14 85.3 ± 14 85.1 ± 13
Mean 88.6 ± 13 86.6 ± 14† 86.5 ± 13†
Fat Mass
(kg)
HC-GCM 37.5 ± 7 36.3 ± 9 35.8 ± 8 D = 0.81
HC-P 37.8 ± 8 36.1 ± 9 35.4 ± 8 S = 0.98
HP-GCM 38.9 ± 6 36.4 ± 7 35.9 ± 6 T = 0.001
HP-P 38.0 ± 8 37.1 ± 8 36.8 ± 8 T × D = 0.93
HC 37.7 ± 8 36.2 ± 8 35.6 ± 8 T × S = 0.53
HP 38.6 ± 6 36.6 ± 7 36.2 ± 8 T × D × S = 0.19
GCM 38.3 ± 6 36.3 ± 7 35.8 ± 7
P 37.9 ± 8 36.5 ± 8 35.9 ± 8
Mean 38.1 ± 7 36.4 ± 8† 35.9 ± 7†
FFM
(kg)
HC-GCM 44.4 ± 7 44.7 ± 8 45.5 ± 8 D = 0.74
HC-P 42.8 ± 6 42.8 ± 7 42.8 ± 6 S = 0.45
HP-GCM 45.7 ± 7 45.5 ± 7 45.8 ± 8 T = 0.57
HP-P 44.5 ± 7 42.9 ± 6 43.8 ± 7 T × D = 0.09
HC 43.5 ± 7 43.6 ± 7 44.0 ± 7 T × S = 0.12
HP 45.3 ± 7 44.6 ± 6 45.1 ± 7 T × D × S = 0.77
GCM 45.2 ± 7 45.1 ± 7 45.6 ± 8
P 43.4 ± 6 42.9 ± 6 43.2 ± 6
Mean 44.3 ± 7 44.1 ± 7 44.5 ± 7
Body Fat
(%)
HC-GCM 45.7 ± 3 44.6 ± 3 43.9 ± 3 D = 0.98
HC-P 46.7 ± 4 45.5 ± 4 45.0 ± 3 S = 0.41
HP-GCM 46.0 ± 3 44.3 ± 3 43.9 ± 3 T = 0.001
HP-P 45.8 ± 2 46.1 ± 3 45.4 ± 2 T × D = 0.46
HC 46.3 ± 4 45.1 ± 4 44.5 ± 3 T × S = 0.21
HP 45.9 ± 2 44.9 ± 2 44.4 ± 3 T × D × S = 0.25
GCM 45.9 ± 3 44.4 ± 3 43.9 ± 3
P 46.4 ± 4 45.7 ± 4 45.1 ± 4
Mean 46.1 ± 3 45.0 ± 3† 44.5 ± 3†
REE
(kcals/d)
HC-GCM 1,548 ± 262 - 1,453 ± 302 D = 0.73
HC-P 1,400 ± 180 - 1,388 ± 218 S = 0.35
HP-GCM 1,517 ± 301 - 1,519 ± 310 T = 0.26
HP-P 1,477 ± 301 - 1,410 ± 147 T × D = 0.78
HC 1,465 ± 225 - 1,416 ± 251 T × S = 0.93
HP 1,504 ± 289 - 1,485 ± 268 T × D × S = 0.32
GCM 1,530 ± 276 - 1,490 ± 298
P 1,424 ± 213 - 1,394 ± 193
Mean 1,482 ± 251 - 1,447 ± 257
Data are means ± standard deviations. HC = high carbohydrate diet, HP = high protein diet, GCM = glucosamine/chondroitin/MSM group, P = placebo group,
FFM = fat free mass, REE = resting energy expenditure, D = diet, S = supplement, T = time. † Indicates p < 0.05 difference from baseline.
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Page 9 of 17(-14%), creatinine (-15%), uric acid (-9%), alanine amino-
transaminase (-23%), HOMAIR (-17%), and leptin (-30%)
values while glucose (-7%) values tended to be lower. As
expected, training moderately increased creatine kinase
levels (49%) and tended to increase C-reactive protein
values (44%). No significant differences were observed
remaining whole blood and serum markers assayed.
Psychosocial and pain questionnaires
Table 8 presents WOMAC, VAS, and QOL results
observed. No significant group or group × time interac-
tions were observed among groups. Therefore, data are
presented for mean time effects. Participants experi-
enced significant reductions in WOMAC perceptions of
pain (-53%), joint stiffness (-44%), and limitations in
physical function (-49%) during the course of the study
with no group or group × time interactions observed.
Likewise, VAS pain was decreased by 59% during the
course of the study. Trends were observed in time by
diet (p = 0.10) and time × supplement (p = 0.08) inter-
actions with a moderate to large effect size observed
(d = 1.1) but results were too inconsistent to support
claims that GCM supplementation lessens perceptions
of knee pain in active individuals. Participants also
experienced significant improvements in QOL measures
of physical functioning (59%), vitality (120%), and social
function (66%) with no significant differences observed
among diet and supplement groups.
Discussion
Osteoarthritis is a degenerative disease that is character-
ized by focal erosive lesions, cartilage destruction, sub-
chondral sclerosis, cyst formation, and large osteophyte
f o r m a t i o na tj o i n tm a r g i n st h a tr e s u l ti nt h es t r u c t u r a l
and functional failure of synovial joints [13,40]. It is the
most prevalent musculoskeletal disorder diagnosed in
the United States which affects nearly 15% of Americans
and costs an estimated $80 billion dollars annually [41].
Athletes with prior knee injuries and individuals who
maintain an active lifestyle as they age are also at risk to
experience knee pain or degenerative joint issues
[5,27,28]. Although the etiology of OA involves multiple
factors, obesity has been identified as a primary risk fac-
tor involved in the development of the disease [9]. Indi-
viduals with a BMI greater than 30 kg/m
2 are four times
as likely to have knee OA than those with a BMI less
than 25.0 kg/m
2 [9]. Although the specific amount of
weight loss needed to improve or prevent OA has yet to
be determined, empirical research has found that for
every one pound of weight loss, there is a four pound
reduction in knee joint load per step [42]. With such a
drastic reduction in pressure on OA affected knees, alle-
viating obesity through weight loss has been suggested
to be among the most beneficial methods of relieving
pressure on osteoarthritic joints.
Participation in a therapeutic exercise program has
been reported to aid in the management of OA symp-
toms [12,43,44]. The American College of Sports Medi-
cine recommends that OA patients engaged in daily
static stretching exercises to improve flexibility; low
intensity resistance training involving major muscle
Figure 2 Changes in body composition variables among
groups after 10 and 14 weeks of dieting and training.
Table 3 Knee range of motion data and circumference data for the diet and supplement groups
Variable 0 Weeks
10
14 Group p-level
Time
G×T
Range of Motion
Extension - RL (deg) 3.02 ± 2.6 4.20 ± 3.0 4.05 ± 3.1 0.12 0.13 0.56
Extension - LL (deg) 3.02 ± 2.6 4.34 ± 3.2† 4.11 ± 3.2 0.66 0.06 0.35
Flexion - RL (deg) 123.9 ± 7 125.2 ± 7 121.6 ± 8 0.33 0.34 0.07
Flexion - LL (deg) 121.2 ± 8 126.3 ± 6† 126.7 ± 8† 0.80 0.001 0.33
Circumference
Right Knee (cm) 36.9 ± 3 36.6 ± 3 37.8 ± 5 0.82 0.34 0.20
Left Knee (cm) 36.6 ± 4 36.6 ± 3 39.1 ± 5 0.92 0.06 0.18
Data are means ± standard deviations for time main effects. RL = right leg, LL = left leg, G = group, T = time. † Indicates p < 0.05 difference from baseline.
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Page 10 of 17groups (10-12 repetitions, 40-60% of 1RM, 2-3 d/week);
and, aerobic exercise (40-60% of peak VO2,u pt o3 0 -
min, 3-5 d/week) as tolerated [45,46]. Regular exercise
has also been reported to improve the balance and func-
tionality of overweight and obese individuals with knee
OA [8]. Therefore, exercise and weight loss have been
recommended as effective strategies in managing symp-
toms of OA [8-10,12,13,42,43,47].
A number of studies support these recommendations.
For example, Felson and colleagues [7] reported that
weight loss reduced the risk for development of OA in
women. Christensen and associates [10] reported that
OA patients following a low-energy diet (~840 kcal/d)
that included weekly dietary counseling sessions was
more effective in promoting weight loss (11.1% vs. 4.3%)
and improving WOMAC index scores (-35% vs. -14%)
than patients educated about weight loss who maintained
a moderately hypo-energetic diet (~1,200 kcal/d). Simi-
larly, Miller and coworkers [9] reported that older obese
adults with symptomatic knee OA who followed an
intensive weight loss program for 6-months that included
meal replacement bars and drinks (~1,000 kcal/d) experi-
enced greater weight loss (0.1% vs. 8.5%), fat loss (0.08%
vs. 23.2%); and, improvement in WOMAC scores (-5%
vs. -33%), 6-min walking distance (2.3% vs. 16.7%), and
stair climb time (7.5% vs. -16.3%) than those who main-
tained weight. Penninx and associates [47] reported that
aerobic and resistance exercise may reduce and/or pre-
vent the incidence of disability in activities of daily living
in patients with knee OA. Finally, Messier and coworkers
[8] examined the effects of long-term weight loss and
exercise on self-reported physical function in older obese
adults with knee OA. Participants followed a diet pro-
gram, an exercise program that involved aerobic and
resistance-exercise, a diet plus exercise intervention, or
usual care. The researchers found that participants fol-
lowing the diet plus exercise program experienced signifi-
cant improvements in self-reported physical function,
Table 4 Exercise performance related data for the diet and supplemented groups
Variable Group 0 Week
10
14 p-value
Peak VO2 HC-GCM 19.4 ± 3 19.9 ± 4 20.5 ± 3† D = 0.85
(ml/kg/min) HC-P 18.3 ± 5 18.5 ± 6 19.6 ± 4† S = 0.20
HP-GCM 20.2 ± 4 21.4 ± 4 21.9 ± 3†* T = 0.05
HP-P 18.7 ± 4 18.8 ± 2 16.9 ± 3†* T × D = 0.03
HC 18.8 ± 4 19.1 ± 5 20.0 ± 4† T × S = 0.008
HP 19.8 ± 4 20.6 ± 4†* 20.3 ± 4† T × D × S = 0.003
GCM 19.9 ± 3 20.8 ± 4†* 21.3 ± 3†*
P 18.4 ± 5 18.6 ± 5 18.8 ± 4
Mean 19.2 ± 4 19.8 ± 4 20.1 ± 4†
Bench Press HC-GCM 26.9 ± 5 29.1 ± 8 29.8 ± 8 D = 0.57
1RM (kg) HC-P 27.0 ± 7 28.2 ± 6 29.5 ± 6 S = 0.19
HP-GCM 29.8 ± 6 33.8 ± 7 34.6 ± 6 T = 0.001
HP-P 24.4 ± 2 28.4 ± 3 27.8 ± 5 T × D = 0.18q
HC 27.0 ± 6 28.7 ± 7 29.7 ± 7 T × S = 0.57
HP 28.1 ± 5 32.1 ± 6 32.5 ± 6 T × D × S = 0.75
GCM 28.5 ± 6 31.8 ± 7 32.5 ± 7
P 26.2 ± 6 28.7 ± 7 29.0 ± 6
Mean 27.5 ± 6 30.2 ± 6† 30.9 ± 7†
Upper Body Endurance (kg) HC-GCM 206 ± 52 269 ± 121 245 ± 120 D = 0.81
HC-P 164 ± 88 175 ± 109 198 ± 142 S = 0.02
HP-GCM 242 ± 81 299 ± 128 278 ± 116 T = 0.04q
HP-P 157 ± 22 179 ± 34 153 ± 26 T × D = 0.59
HC 182 ± 75 216 ± 120 219 ± 131 T × S = 0.17q
HP 216 ± 66 262 ± 120 240 ± 113 T × D × S = 0.64
GCM 226 ± 59 286 ± 122 264 ± 115
P 162 ± 73 176 ± 90 184 ± 119
Mean 197 ± 72 237 ± 120† 228 ± 121
Data are means ± standard deviations. HC = high carbohydrate, HP = high protein, GCM = glucosamine/chondroitin/MSM, P = placebo, HR = heart rate, SBP =
systolic blood pressure, DBP = diastolic blood pressure, VO2 = oxygen uptake, 1 RM = one repetition maximum, D = diet, S = supplement, T = time, q =
quadratic alpha level. † Indicates p < 0.05 difference from baseline. * represents p < 0.05 difference between groups.
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Page 11 of 176-min walk distance, stair climb time, and knee pain
compared to those in the usual care group. Exercise
alone improved 6-min walk distance while dieting alone
did not result in greater functional improvement than
usual care.
Present findings support prior reports indicating that
weight loss and exercise training provided therapeutic
benefit for women with knee OA. In this regard, the cir-
cuit style resistance-training program and weight loss
p r o g r a mu s e di nt h i ss t u d yp r omoted significant reduc-
tions in body mass (-2.4%), fat mass (-6%), and body fat
(-3.5%) while increasing symptom-limited peak VO2
(5%), upper body 1RM strength (12%), upper body mus-
cular endurance (20%), isokinetic knee extension and
flexion peak torque (12-46%), step up and over knee
function (8-15%), and forward lunge knee function
(7-20%). These changes were accompanied by significant
improvements in total cholesterol (-8%), low-density
lipoproteins (-12%), HOMAIR (-17%), and leptin (-30%)
values. Interestingly, reductions in serum leptin levels
have been reported to be associated with improved
physical function in patients with OA [48]. Participants
also reported less perceptions of pain (-53%), joint stiff-
ness (-44%), and limitations in physical function (-49%)
o nt h eW O M A Ci n d e xa sw e l la sa5 9 %r e d u c t i o ni n
VAS pain ratings. These findings provide additional evi-
dence that patients with knee OA may experience signif-
icant improvements in markers of health, fitness,
functional capacity, and perceptions of pain when fol-
lowing a weight loss and exercise program that includes
resistance-training.
However, present findings add to our understanding of
how different types of diets and concomitant dietary sup-
plementation with a GCM affect weight loss, training
adaptations, functional capacity, and/or perceptions of
pain in women with knee OA. In this regard, a number
of studies have indicated that replacing carbohydrate
with protein while following a hypo-energetic diet pro-
motes greater fat loss [14,15,19,49]. The rationale has
been that there are thermogenic advantages in metaboliz-
ing protein compared to carbohydrate and that a higher
amount of protein in the diet can help maintain fat free
Table 5 Mean isokinetic knee extension and flexion data observed over time
Variable 0 Weeks
10
14 Group p-level
Time
G×T
5 Repetitions at 60 deg/sec
Peak Torque - RL Extension (kg/m) 9.90 ± 2.0 10.38 ± 2.6 10.69 ± 2.8 0.36 0.13 0.69
Peak Torque - LL Extension (kg/m) 9.15 ± 2.2 10.38 ± 2.6† 10.34 ± 2.9† 0.47 0.04 0.44
Peak Torque - RL Flexion (kg/m) 4.66 ± 1.6 5.53 ± 1.6† 5.99 ± 2.1† 0.62 0.003 0.90
Peak Torque - LL Flexion (kg/m) 4.44 ± 1.6 5.47 ± 1.7† 5.61 ± 1.9† 0.71 0.01 0. 45
Fatigue Index - RL Extension (%) -0.8 ± 50 9.4 ± 18 8.7 ± 25 0.79 0.32 0.54
Fatigue Index - LL Extension (%) 3.5 ± 30 11.1 ± 19 11.0 ± 18 0.73 0.38 0.41
Fatigue Index - RL Flexion (%) -8.8 ± 72 16.9 ± 28† 25.3 ± 13† 0.23 0.02 0.28
Fatigue Index - LL Flexion (%) 12.6 ± 30 19.4 ± 18 23.4 ± 10 0.82 0.12 0.75
10 Repetitions at 180 deg/sec
Peak Torque - RL Extension (kg/m) 6.05 ± 2.3 6.45 ± 2.4 6.82 ± 2.4† 0.12 0.05 0.40
Peak Torque - LL Extension (kg/m) 5.60 ± 2.8 6.40 ± 2.7 6.85 ± 2.3† 0.47 0.04 0.44
Peak Torque - RL Flexion (kg/m) 2.80 ± 1.5 3.70 ± 1.8† 4.10 ± 1.9† 0.35 0.001 0.66
Peak Torque - LL Flexion (kg/m) 2.68 ± 1.7 3.49 ± 1.6† 3.90 ± 1.7† 0.60 0.001 0. 48
Fatigue Index - RL Extension (%) -1.9 ± 33 -9.6 ± 67 9.5 ± 26 0.19 0.12 0.84
Fatigue Index - LL Extension (%) -17.6 ± 55 5.2 ± 27† -0.2 ± 47† 0.08 0.02 0.49
Fatigue Index - RL Flexion (%) -12.1 ± 84 7.9 ± 56† 17.7 ± 22† 0.37 0.08 0.53
Fatigue Index - LL Flexion (%) -48.9 ± 139 9.8 ± 53† 9.7 ± 67† 0.61 0.02 0.44
15 Repetitions at 300 deg/sec
Peak Torque - RL Extension (kg/m) 32.6 ± 13 36.6 ± 14 36.2 ± 15 0.68 0.17 0.39
Peak Torque - LL Extension (kg/m) 31.0 ± 16 36.2 ± 15† 37.0 ± 15† 0.62 0.02 0.12
Peak Torque - RL Flexion (kg/m) 14.8 ± 11 19.0 ± 13† 19.3 ± 13† 0.76 0.02 0.61
Peak Torque - LL Flexion (kg/m) 12.7 ± 11 17.2 ± 12† 17.6 ± 11† 0.82 0.02 0. 24
Fatigue Index - RL Extension (%) 7.8 ± 43 10.8 ± 27 17.2 ± 29 0.46 0.19 0.83
Fatigue Index - LL Extension (%) 4.0 ± 48 11.3 ± 24 17.6 ± 37 0.46 0.25 0.77
Fatigue Index - RL Flexion (%) -2.0 ± 94 14.1 ± 70 17.9 ± 68† 0.52 0.36 0.82
Fatigue Index - LL Flexion (%) -20.2 ± 103 16.3 ± 89† 19.1 ± 62† 0.76 0.02 0.94
Data are means ± standard deviations for time main effects. RL = right leg, LL = left leg, G = group, T = time. † Indicates p < 0.05 difference from baseline.
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tions in resting energy expenditure that is often asso-
ciated with weight loss [14,16]. Our previous research
examining the efficacy of the exercise and diet program
used in this study provides some support to this theory
[20,21,23]. Therefore, we hypothesized that women with
knee OA may experience greater weight loss and thera-
peutic benefits from following a higher protein diet. Pre-
sent findings, however, indicate that women with knee
OA benefited from both a higher carbohydrate and
higher protein diet. Although there was some evidence
that women following the HP diet experienced greater
gains in symptom-limited peak aerobic capacity, no sig-
nificant differences were observed in amount of weight
loss, fat loss, or resting energy expenditure when diets
were compared. Participants in both groups effectively
maintained fat free mass and resting energy expenditure
levels despite experiencing significant reductions in
weight and fat mass. Additionally, no significant differ-
ences were observed between diet types among changes
in strength, muscular endurance, functional tests, or mar-
kers of health. These findings indicate that the type of
diet does not appear to influence weight loss or training
adaptations in sedentary obese women with knee OA
initiating a weight loss and exercise training program.
The lack of statistical significance could be due to the
small sample-size studied and/or that the exercise stimu-
lus was effective enough to negate any additional
metabolic benefits from adherence to a higher protein
diet in this population. Nevertheless, present findings do
not support our hypothesis that women with knee OA
may experience greater benefits from following a higher
protein hypo-energetic diet.
Several studies have also indicated that glucosamine
and/or chondroitin supplementation may provide thera-
peutic benefits in individuals with knee OA. For example,
Reginster and associates [50] reported that 3-years of glu-
cosamine sulphate supplementation (1,500 mg/d) pre-
vented progression of joint-space narrowing and
improved WOMAC scores in patients with knee OA.
Similarly, Pavelka and colleagues [25] found that dietary
supplementation of glucosamine sulfate (1,500 mg/d for
3-years) retarded the clinical progression of knee OA.
Braham et al [51] found that 2,000 mg/d of glucosamine
supplementation for 12-weeks improved markers of qual-
ity of life and self-reported perceptions of knee pain in
individuals with regular knee pain. Usha and coworkers
[26] reported that dietary supplementation of 1,500 mg/d
of glucosamine and/or MSM for 12-weeks produced an
analgesic and anti-inflammatory effect, reduced percep-
tions of pain, and improved functional ability of joints in
patients with mild to moderate knee OA. Moreover,
Matsuno and colleagues [52] investigated the effects of
12-weeks of ingesting a dietary supplement containing
glucosamine hydrochloride (1,200 mg/d), shark cartiliage
powder (300 mg/d), chondroitin (75-111 mg/d), and
Table 6 Functional balance testing results observed over time
Variable 0 Weeks
10
14 Group p-level
Time
G×T
Sit to Stand Function
Weight Transfer (sec) 0.377 ± 0.18 0.355 ± 0.17 0.370 ± 0.22 0.80 0.91 0.89
Rising Index (% body weight) 16.6 ± 4.3 18.6 ± 5.7 18.2 ± 5.6 0.97 0.13 0.34
Sway Velocity (deg/sec) 4.63 ± 1.3 4.56 ± 1.1 4.62 ± 1.2 0.78 0.78 0.12
Step Up and Over Knee Function
Lift-up Index - RL (% body weight) 41.2 ± 9.2 43.6 ± 9.7 44.5 ± 8.6† 0.90 0.01 0.71
Lift-up Index - LL (% body weight) 34.7 ± 8.5 37.4 ± 8.1 38.9 ± 7.2† 0.70 0.002 0.50
Impact Index - RL (% body weight) 48.7 ± 11.2 48.4 ± 12.1 48.3 ± 10.9 0.91 0.70 0.77
Impact Index - LL (% body weight) 52.1 ± 10.6 52.4 ± 13.5 54.5 ± 14.1 0.84 0.22 0.47
Movement Time - RL (sec) 1.73 ± 0.3 1.55 ± 0.2† 1.47 ± 0.2† 0.83 0.001 0.07
Movement Time - LL (sec) 1.76 ± 0.3 1.60 ± 0.5† 1.49 ± 0.3† 0.98 0.002 0.68
Forward Lunge Knee Function
Distance - RL (% body height) 43.2 ± 7 45.6 ± 7† 46.3 ± 7† 0.14 0.001 0.75
Distance - LL (% body height) 42.5 ± 5 45.7 ± 7† 46.2 ± 7† 0.24 0.001 0.49
Impact Index - RL (% body weight) 18.5 ± 5 19.0 ± 7 18.6 ± 5 0.65 0.76 0.77
Impact Index - LL (% body weight) 14.0 ± 5 16.4 ± 7 15.7 ± 5 0.86 0.15 0.97
Contact Time - RL (sec) 1.664 ± 0.5 1.344 ± 0.3† 1.359 ± 0.4† 0.57 0.001 0.81
Contact Time - LL (sec) 1.641 ± 0.7 1.347 ± 0.4† 1.310 ± 0.4† 0.64 0.002 0.98
Force Impulse - RL (% body weight/sec) 168 ± 53 139 ± 36† 141 ± 38† 0.61 0.001 0. 59
Force Impulse - LL (% body weight/sec) 162 ± 65 136 ± 33† 132 ± 37† 0.62 0.002 0. 99
Data are means ± standard deviations for time main effects. RL = right leg, LL = left leg, G = group, T = time. † Indicates p < 0.05 difference from baseline.
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Page 13 of 17quercetin (45 mg/d) on synovial fluid properties of
patients with OA. The researchers reported that the OA
patients experienced significant improvements in pain
symptoms, ability to perform daily activities (walking and
climbing up and down stairs), and changes in synovial
fluid properties. Finally, Ng and coworkers [53] reported
that dietary supplementation of glucosamine sulphate
(1,500 mg/d) for 6-weeks reduced OA symptoms in indi-
viduals walking a minimum of approximately 30-min per
day. These findings provide support to the theory that
glucosamine and chondroitin supplementation may pro-
vide some therapeutic benefits to patients with knee OA.
In the present study, subjects ingested in a double blind
and randomized manner a placebo or a dietary supple-
ment containing 1,500 mg/d of glucosamine, 1,200 mg/d
of chondroitin sulfate, and 900 mg/d of MSM. We found
that symptom-limited peak aerobic capacity was increased
to a greater degree in participants ingesting the GCM sup-
plement with the greatest effects observed in the HP-
GCM group. In addition, mean group upper extremity
muscular endurance was greater in the GCM group com-
pared to the P group. However, GCM supplementation
did not significantly affect remaining markers of isotonic
or isokinetic strength, balance, functional capacity,
markers of health, self-reported perceptions of pain, or
indicators of quality of life. These findings indicate that
GCM supplementation provides only marginal additive
benefit to a resistance-based exercise and weight loss pro-
gram. The lack of additive benefits observed could be due
to limitations in sample size, length of the intervention,
and/or the fact that the exercise intervention resulted in
marked improvement in functional capacity and percep-
tions of pain thereby minimizing the impact of dietary
supplementation of GCM. However, additional research is
needed to examine the influence of GCM supplementation
during a training and weight loss program before definitive
conclusions can be drawn.
Conclusions
Present findings indicate that adherence to a resistance-
based circuit training and weight loss program promoted
weight and fat loss, increased strength and functional
capacity, and improved markers of health in sedentary
obese women with clinically-diagnosed knee osteoarthritis.
Table 7 Fasting serum blood and hormone markers observed over time
Variable 0 Weeks
10
14 Group p-level
Time
G×T
Blood Lipids & Glucose
Triglycerides (mmol/l) 1.71 ± 1.0 1.59 ± 1.0 1.62 ± 1.0 0.91 0.51 0.83
Cholesterol (mmol/l) 5.61 ± 1.0 5.15 ± 0.8† 5.25 ± 1.2 0.05 0.08q 0.78
LDL (mmol/l) 3.65 ± 0.8 3.23 ± 0.6† 3.34 ± 0.9 0.13 0.04 q 0.51
HDL (mmol/l) 1.39 ± 0.3 1.23 ± 0.2† 1.24 ± 0.3† 0.14 0.02 0.96
Glucose (mmol/l) 5.93 ± 0.8 5.69 ± 0.8 5.52 ± 0.9 0.99 0.08 0.96
Serum Protein and Enzymes
BUN (mmol/l) 5.09 ± 1.4 4.85 ± 1.4 4.36 ± 1.4† 0.91 0.006 0.44
Creatinine (1/2 mol/l) 72 ± 15 69 ± 13 61 ± 15† 0.66 0.003 0.68
BUN/Creatinine Ratio 17.6 ± 3.8 17.6 ± 3.7 18.0 ± 4.4 0.63 0.55 0.33
Uric Acid (1/2 mol/l) 328 ± 92 300 ± 68† 300 ± 77† 0.49 0.09 0.93
CK (IU/l) 59 ± 36 87 ± 42† 88 ± 27† 0.23 0.001 0.86
ALT (IU/l) 25.5 ± 11 19.7 ± 6† 22.0 ± 10 0.81 0.008q 0.14
AST (IU/l) 20.0 ± 6 20.0 ± 5 21.8 ± 8 0.95 0.17 0.96
GGT (IU/l) 42.8 ± 30 41.7 ± 32 50.9 ± 45 0.66 0.15 0.23
Hormones
C-Reactive Protein (1/2 mol/l) 4.93 ± 4.3 5.12 ± 4.2 7.12 ± 6.7† 0.84 0.06 0.55
IL-6 (pg/ml) 3.68 ± 3.9 3.54 ± 4.1 3.38 ± 5.0 0.13 0.78 0.16
TNF-a (pg/ml) 0.72 ± 2.9 0.90 ± 3.5 0.96 ± 3.3 0.19 0.71 0.60
Cortisol (nmol/l) 825 ± 827 807 ± 599 846 ± 943 0.75 0.56 0.07
Insulin (pmol/l) 90.7 ± 90 96 ± 104 88 ± 98 0.13 0.58 0.81
Glucose/Insulin Ratio 18.3 ± 20 20.2 ± 26 24.1 ± 29 0.36 0.38 0.67
HOMAIR 3.26 ± 3.5 3.33 ± 4.0 2.69 ± 3.0† 0.07 0.05 0.42
Leptin (1/2 g/l) 185 ± 134 130 ± 86† 134 ± 93† 0.97 0.03 0.51
Data are means ± standard deviations for time main effects. LDL = low density lipoproteins, HDL = high density lipoproteins, BUN = blood urea nitrogen, CK =
creatine kinase, ALT = alanine aminotransferase, AST = aspartate aminotranferase, GGT = gamma glutamyltransferase, IL-6 = interleukin 6, TNF-a = tumor
necrosis factor alpha, HOMAIR = homeostatic model assessment of insulin resistance, G = group, T = time, q = quadratic alpha level. † Indicates p < 0.05
difference from baseline.
Magrans-Courtney et al. Journal of the International Society of Sports Nutrition 2011, 8:8
http://www.jissn.com/content/8/1/8
Page 14 of 17These findings support contentions that exercise and
weight loss may have therapeutic benefits for women with
knee osteoarthritis. Although some trends were observed,
the type of diet and dietary supplementation of GCM pro-
vided marginal additive benefits. However, since diet and
GCM supplementation appeared to affect symptom-
limited peak aerobic capacity and some moderate to large
effect sizes were noted in key variables, additional research
with a larger sample size is needed to determine whether
type of diet and/or GCM supplementation while partici-
pating in an exercise and weight loss program may provide
therapeutic benefits in this population.
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